Microhaem Scientifics was honored to host Dr. James Mwangi, Group Managing Director and Chief Executive Officer of Equity Group Holdings Plc, together with members of the bank’s senior leadership team, for a courtesy visit and strategic engagement at the company’s facilities.The visit focused on the progress of Phase II of Microhaem’s in-vitro diagnostics (IVD) and biologics plant expansion project, a key milestone in advancing Africa’s health sovereignty.
During the engagement, Microhaem shared its strategic roadmap to scale IVD production capacity by fifteen-fold, positioning the company as a leading local manufacturer of high-quality diagnostic test kits. This expansion is designed to reduce reliance on imported healthcare products, strengthen regional supply chains, and improve access to essential diagnostics across Africa.
Dr. Mwangi commended Microhaem’s leadership in driving innovation and capacity building within Africa’s health sector. He emphasized the importance of public–private partnerships in fostering sustainable solutions that align with the continent’s long-term healthcare needs.
In addition to diagnostics, discussions also highlighted Microhaem’s forward-looking investments in advanced medicine, including stem cell research, monoclonal antibody (mAb) therapeutics, and cutting-edge diagnostic technologies. These initiatives reflect the company’s commitment to positioning Africa not only as a consumer of healthcare innovations but also as a global contributor to modern medical science.
Speaking on behalf of Equity Group Holdings Plc, Dr. Mwangi reaffirmed the bank’s commitment to supporting enterprises that strengthen Africa’s self-sufficiency. He noted that Microhaem’s efforts demonstrate how local innovation and manufacturing can deliver world-class products that meet international standards while remaining accessible and affordable to African healthcare facilities.
The visit was marked by moments of collaboration and shared vision, underscoring the central role of trust, partnership, and innovation in building a resilient African healthcare ecosystem.
⸻
About Microhaem Scientifics
Microhaem Scientifics (MHS) is a leading African manufacturer of high-quality diagnostics and biologics. With a mission to advance Africa’s health sovereignty, MHS focuses on innovation, self-reliance, and the delivery of internationally accredited healthcare solutions. The company’s product portfolio includes rapid test kits for HIV, malaria, sickle cell disease, and other high-burden conditions, as well as new frontiers in advanced therapeutics.
